SCHEDULE 13G: BlackRock Discloses 5.6% Passive Stake in Pyxis Oncology, Inc.
Beneficial Ownership Disclosure
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.6% beneficial ownership stake in Pyxis Oncology, Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 3,344,141 shares of Pyxis Oncology, Inc. Common Stock.
- This stake represents 5.6% of the total outstanding shares of Pyxis Oncology, Inc.
- BlackRock, Inc. holds sole voting power over 3,290,208 shares and sole dispositive power over 3,344,141 shares.
- The filing is a Schedule 13G, indicating that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Pyxis Oncology, Inc.
- The beneficial ownership is held through various BlackRock business units, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Asset Management Ireland Limited, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC.
Sentiment
Score: 5
Explanation: The document is a factual, regulatory disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- BlackRock, Inc., a prominent global asset manager, has disclosed a significant 5.6% beneficial ownership stake in Pyxis Oncology, Inc., which can be viewed as a signal of institutional interest.
Future Outlook
NA
Management Comments
- BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Pyxis Oncology, Inc., nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, potentially offering a signal of institutional interest.
- Management: Awareness of a large, passive institutional investor on the shareholder register.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of the previously issued Power of Attorney that was expressly revoked by the new Power of Attorney. |
| 12/31/2024 | Date of event which requires the filing of this statement (reporting period end date for ownership). |
| 01/21/2025 | Date of the new Power of Attorney document authorizing individuals to sign SEC filings for BlackRock, Inc. |
| 02/04/2025 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Pyxis Oncology, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.